Journal of Clinical Psychopharmacology · 2004 · 105 citations · 22 references
PharmacyPharmacotherapyPsychiatryClinical PharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyDepression ManagementDepression PharmacotherapyTreatment-resistant Psychiatric DisordersAntidepressant MedicationsAntidepressant ResponseAntidepressant SafetyAntidepressant TolerabilityClinical RemissionPlacebo-controlled Efficacy AssessmentSelective Serotonin Reuptake Inhibitor TreatmentSelective Serotonin Reuptake Inhibitor Use
BACKGROUND: The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine. METHOD: Thirty antidepressant-treated adult outpatients with persisting major depressive disorder received 800 to 1600 mg of S-adenosyl-L-methionine tosylate over a 6-week trial. RESULTS: Intent-to-treat analyses based on the Hamilton Depression Rating Scale revealed a response rate of 50% and a remission rate of 43% following augmentation with S-adenosyl-L-methionine. Gastrointestinal symptoms and headaches were the most common side effects. CONCLUSION: Augmentation of selective serotonin reuptake inhibitors or venlafaxine with S-adenosyl-L-methionine warrants a placebo-controlled trial in resistant depression.
22